ArticleSisli Etfal Hastanesi tip bulteni2026
Ventilator-Associated Pneumonia in Newborns: Distribution of Causative Agents and Antibiogram.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence for the Efficacy and Safety of Tigecycline for the Treatment of Ventilator-Associated Pneumonia in Preterm Infants: A Systematic Review.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To characterize pathogen distribution and antibiograms in neonatal ventilator-associated pneumonia (VAP) and to examine clinical correlates of recurrent growth and colonization. Methods: This was a single-center retrospective cohort study conducted between September 1, 2020, and September 1, 2025. Among 152 neonates with tracheal aspirate culture (TAC) growth, 61 met the VAP criteria; 48 with complete clinical and antibiogram data were analyzed. Recurrent growth was defined as a second positive TAC with a different species obtained at another time point, and colonization was defined as the same organism in ≥3 consecutive TACs. Demographics, inflammatory biomarkers, blood cultures, and EUCAST susceptibilities were recorded. Group comparisons were performed using the Mann-Whitney U test and Fisher's exact test; temporal susceptibility trends were assessed using Spearman's rho. Results: Gram-negative organisms predominated. The most frequent first TAC isolates were Conclusion: In our tertiary NICU, neonatal VAP is predominantly caused by multidrug-resistant gram-negative organisms, particularly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.